{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:17:05Z","timestamp":1781619425367,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Subretinal macular hemorrhage (SRMH) is a vision-threatening condition with no consensus on optimal treatment. This study evaluated the outcomes of five treatment modalities and their correlation with patient characteristics and optical coherence tomography findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review was conducted on 120 SRMH patients treated at Oslo University Hospital between October 24, 2015, and December 27, 2022. Best-corrected visual acuity (BCVA) was assessed before and 1-month after treatment. Statistical analyses were performed to evaluate the impact of treatment timing, hemorrhage size, and different therapeutic interventions on visual outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Early intervention, particularly within 7 days of symptom onset, was associated with better median BCVA 1-month post-surgery. A 14-day cut-off showed no benefit. Patients with smaller hemorrhages (&lt;\u20094500\u00a0\u03bcm) had significantly higher BCVA before treatment, but no statistical difference was observed 1-month after treatment. Combination therapies, including tissue plasminogen activator (tPA) with Sulfur Hexafluoride (SF6) gas and tPA with SF6 gas plus anti-vascular endothelial growth factor (anti-VEGF), resulted in significantly improved visual outcomes 1-month post-surgery, but no intervention outperformed others at the 1-month endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early intervention, particularly within 7 days of symptom onset, may improve visual outcomes in SRMH. Combined therapies involving tPA, gas and anti-VEGF appear to be more effective. Further studies with extended follow-up are needed to establish definitive treatment guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Translational relevance<\/jats:title>\n                    <jats:p>This study highlights the importance of early intervention and individualized treatment strategies in managing SRMH. The findings contribute valuable insights into the effectiveness of combination therapies, offering guidance for clinicians and informing future research on evidence-based treatment guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00749-3","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T08:55:16Z","timestamp":1763801716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of subretinal macular hemorrhage treatment: a 7-year retrospective cohort study at Oslo University Hospital"],"prefix":"10.1186","volume":"11","author":[{"given":"Krystian Andrzej","family":"Dziedzic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Confalonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta \u00c9va","family":"Petrovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyubomyr","family":"Lytvynchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnheidur","family":"Bragadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Borjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xhevat","family":"Lumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Petrovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"2","key":"749_CR1","first-page":"97","volume":"213","author":"A Scupola","year":"1999","unstructured":"Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 1999;213(2):97\u2013102.","journal-title":"Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd"},{"key":"749_CR2","unstructured":"Shukla UV, Kaufman EJ. Intraocular hemorrhage. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 3]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567779\/."},{"issue":"1","key":"749_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/IAE.0b013e3181e91148","volume":"31","author":"M Moriyama","year":"2011","unstructured":"Moriyama M, Ohno-Matsui K, Shimada N, Hayashi K, Kojima A, Yoshida T, et al. Correlation between visual prognosis and fundus autofluorescence and optical coherence tomographic findings in highly myopic eyes with submacular hemorrhage and without choroidal neovascularization. Retina Phila Pa. 2011;31(1):74\u201380.","journal-title":"Retina Phila Pa"},{"issue":"2","key":"749_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00417-008-0958-5","volume":"247","author":"SK Gibran","year":"2009","unstructured":"Gibran SK, Romano MR, Wong D. Perfluorocarbon liquid assisted large retinal epithelium patching in sub-macular hemorrhage secondary to age related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):187\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"749_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/08820538.2013.807849","volume":"30","author":"S Nayak","year":"2015","unstructured":"Nayak S, Padhi TR, Basu S, Das T. Pneumatic displacement and Intra-vitreal bevacizumab in management of Sub-retinal and Sub-retinal pigment epithelial hemorrhage at macula in polypoidal choroidal vasculopathy (PCV): rationale and outcome. Semin Ophthalmol. 2015;30(1):53\u20135.","journal-title":"Semin Ophthalmol"},{"issue":"6","key":"749_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/ICU.0000000000000100","volume":"25","author":"C Thuruthumaly","year":"2014","unstructured":"Thuruthumaly C, Yee DC, Rao PK. Presumed ocular histoplasmosis. Curr Opin Ophthalmol. 2014;25(6):508.","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"749_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00417-007-0724-0","volume":"246","author":"H Nakamura","year":"2008","unstructured":"Nakamura H, Hayakawa K, Sawaguchi S, Gaja T, Nagamine N, Medoruma K. Visual outcome after vitreous, sub-internal limiting membrane, and\/or submacular hemorrhage removal associated with ruptured retinal arterial macroaneurysms. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2008;246(5):661\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"2","key":"749_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1159\/000526068","volume":"13","author":"F Confalonieri","year":"2022","unstructured":"Confalonieri F, Stene-Johansen I, Lumi X, Petrovski G. Intravitreal r-tPA injection and pneumatic displacement for submacular retinal hemorrhage: A case series. Case Rep Ophthalmol. 2022;13(2):630\u20137.","journal-title":"Case Rep Ophthalmol"},{"issue":"1","key":"749_CR9","doi-asserted-by":"publisher","first-page":"14875","DOI":"10.1038\/s41598-022-18619-5","volume":"12","author":"Y Mun","year":"2022","unstructured":"Mun Y, Park KH, Park SJ, Cho HJ, Kim CG, Kim JW, et al. Comparison of treatment methods for submacular hemorrhage in neovascular age-related macular degeneration: Conservative versus active surgical strategy. Sci Rep. 2022;12(1):14875.","journal-title":"Sci Rep"},{"issue":"13","key":"749_CR10","first-page":"662","volume":"55","author":"GF McGowan","year":"2014","unstructured":"McGowan GF, Steel D, Yorston D. AMD with submacular hemorrhage: new insights from a population-based study. Invest Ophthalmol Vis Sci. 2014;55(13):662.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"749_CR11","first-page":"723","volume":"109","author":"CA Toth","year":"1991","unstructured":"Toth CA, Morse LS, Hjelmeland LM, Landers MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol Chic Ill 1960. 1991;109(5):723\u20139.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"4","key":"749_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0002-9394(14)72107-5","volume":"122","author":"MH Berrocal","year":"1996","unstructured":"Berrocal MH, Lewis ML, Flynn HW. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol. 1996;122(4):486\u201393.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"749_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.taap.2004.06.021","volume":"202","author":"G Papanikolaou","year":"2005","unstructured":"Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005;202(2):199\u2013211.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"749_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0039-6257(97)00089-1","volume":"42","author":"MA Hochman","year":"1997","unstructured":"Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol. 1997;42(3):195\u2013213.","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"749_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/0002-9394(82)90301-4","volume":"94","author":"H Glatt","year":"1982","unstructured":"Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94(6):762\u201373.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"749_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1600-0420.2006.00736.x","volume":"84","author":"W Soliman","year":"2006","unstructured":"Soliman W, Lund-Andersen H, Larsen M. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. Acta Ophthalmol Scand. 2006;84(5):707\u20138.","journal-title":"Acta Ophthalmol Scand"},{"issue":"6","key":"749_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.ajo.2013.01.012","volume":"155","author":"G Shienbaum","year":"2013","unstructured":"Shienbaum G, Garcia Filho CAA, Flynn HW, Nunes RP, Smiddy WE, Rosenfeld PJ. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Am J Ophthalmol. 2013;155(6):1009\u201313.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"749_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ajo.2015.01.024","volume":"159","author":"JY Shin","year":"2015","unstructured":"Shin JY, Lee JM, Byeon SH. Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage. Am J Ophthalmol. 2015;159(5):904\u2013e9141.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"749_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/IAE.0000000000000295","volume":"35","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Koh KM, Kim JH, Kim HS, Han JI, Lew YJ, et al. Intravitreal Ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration. Retina Phila Pa. 2015;35(2):205\u201312.","journal-title":"Retina Phila Pa"},{"key":"749_CR20","unstructured":"Hughes RE, Tadi P, Bollu PC. TPA therapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482376\/."},{"issue":"3","key":"749_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00006982-199616030-00001","volume":"16","author":"RL Avery","year":"1996","unstructured":"Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in agerelated macular degeneration. Retina. 1996;16(3):183.","journal-title":"RETINA"},{"key":"749_CR22","doi-asserted-by":"publisher","first-page":"2050313X2097033","DOI":"10.1177\/2050313X20970337","volume":"8","author":"A Karamitsos","year":"2020","unstructured":"Karamitsos A, Papastavrou V, Ivanova T, Cottrell D, Stannard K, Karachrysafi S, et al. Management of acute submacular hemorrhage using intravitreal injection of tissue plasminogen activator and gas: A case series. SAGE Open Med Case Rep. 2020;8:2050313X20970337.","journal-title":"SAGE Open Med Case Rep"},{"issue":"7","key":"749_CR23","doi-asserted-by":"publisher","first-page":"e0271447","DOI":"10.1371\/journal.pone.0271447","volume":"17","author":"N Inoue","year":"2022","unstructured":"Inoue N, Kato A, Araki T, Kimura T, Kinoshita T, Okamoto F, et al. Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey. PLoS ONE. 2022;17(7):e0271447.","journal-title":"PLoS ONE"},{"issue":"1","key":"749_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s12886-024-03794-y","volume":"24","author":"A Hillenmayer","year":"2024","unstructured":"Hillenmayer A, Wertheimer CM, Hillenmayer M, Strehle LD, Hartmann LM, Vounotrypidis E, Wolf A. Comparison of different treatment options in submacular haemorrhage. BMC Ophthalmol. 2024;24(1):525. https:\/\/doi.org\/10.1186\/s12886-024-03794-y. PMID: 39654042; PMCID: PMC11626755.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"749_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000505752","volume":"243","author":"E Maggio","year":"2020","unstructured":"Maggio E, Peroglio Deiro A, Mete M, Sartore M, Polito A, Prigione G, Guerriero M, Pertile G. Intravitreal Recombinant tissue plasminogen activator and sulphur hexafluoride gas for submacular haemorrhage displacement in Age-Related macular degeneration: looking behind the blood. Ophthalmologica. 2020;243(3):224\u201335. Epub 2020 Jan 7. PMID: 31905361.","journal-title":"Ophthalmologica"},{"issue":"12","key":"749_CR26","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/jamaophthalmol.2024.4297","volume":"142","author":"GSP Murphy","year":"2024","unstructured":"Murphy GSP, Saleh A, Ayis S, Cheema MR, Mehta A, Steel DH, Membrey L, Costen M, Jackson TL. Tissue plasminogen activator or perfluoropropane for submacular hemorrhage in Age-Related macular degeneration: A factorial randomized clinical trial. JAMA Ophthalmol. 2024;142(12):1157\u201364. PMID: 39418015; PMCID: PMC11581748.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"749_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13063-025-08727-8","volume":"26","author":"CN Lee","year":"2025","unstructured":"Lee CN, Desai R, Ramazzotto L, Wafa H, Wang Y, Bunce C, Doungsong K, Ezeofor V, Edwards RT, Lois N, Steel DH, Peto T, Hillenkamp J, van Meurs JC, Reeves BC, Jackson TL. Vitrectomy, subretinal tissue plasminogen activator and intravitreal gas for submacular haemorrhage secondary to exudative Age-Related macular degeneration (TIGER): update to study protocol and addition of a statistical analysis plan and health economic analysis plan for a randomised controlled surgical trial. Trials. 2025;26(1):131. https:\/\/doi.org\/10.1186\/s13063-025-08727-8. PMID: 40229856; PMCID: PMC11995560.","journal-title":"Trials"},{"key":"749_CR28","doi-asserted-by":"crossref","unstructured":"He X, Cao W, Wang Z, Zhang N, Xu K, Yu L, et al. Efficacy evaluation of tissue plasminogen activator with anti-vascular endothelial growth factor drugs for submacular hemorrhage treatment: a meta-analysis. J Clin Med [Internet]. 2023 Feb [cited 2024 Jul 9];12(3). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9918283\/.","DOI":"10.3390\/jcm12031035"},{"issue":"2","key":"749_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/jcm13020367","volume":"13","author":"F Confalonieri","year":"2024","unstructured":"Confalonieri F, Ferraro V, Barone G, Di Maria A, Petrovski B\u00c9, Vallejo Garcia JL, et al. Outcomes in the treatment of subretinal macular hemorrhage secondary to Age-Related macular degeneration: A systematic review. J Clin Med. 2024;13(2):367.","journal-title":"J Clin Med"},{"issue":"33","key":"749_CR30","doi-asserted-by":"publisher","first-page":"23928","DOI":"10.1074\/jbc.M113.487884","volume":"288","author":"P Subramanian","year":"2013","unstructured":"Subramanian P, Locatelli-Hoops S, Kenealey J, DesJardin J, Notari L, Becerra SP. Pigment Epithelium-derived factor (PEDF) prevents retinal cell death via PEDF receptor (PEDF-R). J Biol Chem. 2013;288(33):23928\u201342.","journal-title":"J Biol Chem"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00749-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:25:05Z","timestamp":1781616305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00749-3","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}